Botanical decision model to identify evidence thresholds suggested by OAM's Jonas.
This article was originally published in The Tan Sheet
Executive Summary
BOTANICAL CLINICAL EVALUATION MODEL TO ALLOW "INTERMEDIATE DECISIONS" on the usefulness of a substance was suggested by NIH Office of Complementary and Alternative Medicine Director Wayne Jonas, MD, at a Drug Information Association meeting in Washington, D.C. Jan. 28. Jonas discussed an approach for botanicals that he said "might allow us to break out of the rigid boundaries" of current clinical efficacy testing requirements and allow for a less expensive, less complicated testing program.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning